Gilead Sciences, Inc., said on Friday additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery in severely ill COVID-19 patients. Findings from an analysis of its late-stage study showed that 74.4 percent of remdesivir-treated patients recovered by day 14 versus 59 percent of patients receiving …
Read More »
Officials in Brussels have approved remdesivir to treat severe cases of Covid-19, just days after the US effectively stockpiled the world’s entire supply of the antiviral medication. “We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus,” EU health commissioner Stella Kyriakides …
Read More »
The Trump administration has bought up virtually the entire stock for the next three months of one of the drugs proven to work against Covid-19, leaving none for the UK, Europe, or most of the rest of the world. On Monday the US Department of Health and Human Services (HSS) …
Read More »
Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries, it said on Monday, setting the price of a five-day course at $2,340 per patient. The price for U.S. private insurance companies will be $520 per …
Read More »
Japan on Thursday approved Gilead Sciences Inc’s remdesivir as a treatment for COVID-19, making it the country’s first officially authorized drug to tackle the coronavirus disease. Japan reached the decision just three days after the U.S. drugmaker filed for fast-track approval for the treatment. “There has so far been no …
Read More »
The Food and Drug Administration (FDA) plans to authorize the emergency use of remdesivir to treat those infected with the coronavirus. The experimental antiviral drug is being tested on patients as a treatment for Covid-19. Both Dr. Anthony Fauci and President Donald Trump have expressed optimism about early results from …
Read More »
Wall Street looked set to jump at open on Wednesday after Gilead Sciences (GILD.O) reported an encouraging update on a potential COVID-19 treatment, while upbeat earnings reports from Google-parent Alphabet and Boeing boosted the mood. Gilead Sciences Inc (GILD.O) jumped 9.3% in premarket trading after the drugmaker said its experimental …
Read More »
Alghadeer TV Alghadeer TV